Insulin regulated aminopeptidase: a new cardiovascular target

胰岛素调节氨肽酶：新的心血管靶点

• 批准号: nhmrc : 1024100
• 负责人: A/Pr Siew Yeen Chai
• 金额: $ 44.85万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/insulin-regulated-aminopeptidase-cardiovascular-target/110318
• 关键词: Insulin; regulated; aminopeptidase; new; cardiovascular

Cardiovascular disease, leading to heart attack or stroke is the largest cause of death in Australia. We have evidence that inhibition of a newly described enzyme (IRAP) by angiotensin IV is protective in a model of atherosclerosis. Excitingly we have preliminary data indicating that mice deficient in IRAP have better vascular function therefore we will further investigate this as well as the effectiveness of newly developed IRAP inhibitors in preventing development of cardiovascular disease.

导致心脏病发作或中风的心血管疾病是澳大利亚最大的死亡原因。我们有证据表明，血管紧张素IV抑制一种新描述的酶（IRAP）在动脉粥样硬化模型中具有保护作用。令人兴奋的是，我们有初步数据表明IRAP缺陷的小鼠具有更好的血管功能，因此我们将进一步研究这一点以及新开发的IRAP抑制剂在预防心血管疾病发展中的有效性。